Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma-Reference-Cited by-同舟云学术

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma

Published:2022-09-20 Issue:6 Volume:109 Page:719-727
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Daniel Adrien¹,Ghez David²,Ravaiau Camille³,Cavalieri Doriane⁴,Tournilhac Olivier⁴,Herbaux Charles⁵,Roriz Mélanie⁶,Wemeau Mathieu⁷,Guillet Stéphanie⁸,Bossard Jean Baptiste⁹,Hélène Demarquette¹⁰,Kaphan Eleonore¹¹,Caroline Regny¹²,Florence Lachenal¹²,Pierache Adeline¹³,Michel Marc⁸^ORCID,Godeau Bertrand⁸,Terriou Louis¹⁴

Affiliation:

1. Department of Hematology Claude Huriez University Hospital Lille France

2. Department of Hematology and INSERM UMR1030 Gustave Roussy Villejuif France

3. Department of Internal Medicine Angers University Hospital Angers France

4. Department of Hematology Estaing University Hospital Clermont‐Ferrand France

5. Department of Hematology St Eloi University Hospital Montpellier France

6. Department of Internal Medicine Agen‐Nérac Hospital Agen France

7. Department of Hematology Victor Provo Hospital Roubaix France

8. Department of Internal Medicine Henri‐Mondor University Hospital, Assistance Publique des Hôpitaux de Paris Paris France

9. Department of Hematology Lens Hospital Lens France

10. Department of Hematology Dunkerque Hospital Dunkerque France

11. Department of Hematology Grenoble‐Alpes University Hospital Grenoble France